Ocuphire Pharma has been granted a patent for a method to synthesize highly pure phentolamine mesylate. The patent includes a claim for phentolamine mesylate with specific X-ray powder diffraction patterns, water content, and impurity levels. GlobalData’s report on Ocuphire Pharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Ocuphire Pharma, Cancer treatment biomarkers was a key innovation area identified from patents. Ocuphire Pharma's grant share as of May 2024 was 40%. Grant share is based on the ratio of number of grants to total number of patents.
Highly pure phentolamine mesylate with specific xrpd pattern
A recently granted patent (Publication Number: US11976044B2) discloses a novel form of phentolamine mesylate with specific characteristics. The patent claims that the phentolamine mesylate exhibits a unique X-ray powder diffraction pattern with specific peaks at certain degrees 2-theta. Additionally, the phentolamine mesylate contains a defined amount of water and less than 1% of another impurity by weight. The patent further specifies variations in the water content and impurity levels within the phentolamine mesylate, highlighting the importance of purity and composition in this pharmaceutical compound.
Furthermore, the patent details the identification of the impurity as Compound 1 or other specified substances, emphasizing the need for stringent control over impurity levels in the phentolamine mesylate. The patent also sets limits on the amount of impurity allowed in the compound, ensuring high purity standards are maintained. Additionally, the patent includes a broad claim covering various aspects of the phentolamine mesylate's composition, providing a comprehensive overview of the specific characteristics and purity requirements for this form of the compound. Overall, the patent aims to protect this unique formulation of phentolamine mesylate, highlighting its distinct properties and purity standards in pharmaceutical applications.
To know more about GlobalData’s detailed insights on Ocuphire Pharma, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
